Lisa LaMotta

Dec 18, 2024 | insights.citeline.com | Lisa LaMotta

Abbott Nutrition Sales Weakened By China Recall21 Oct 2013 • By Lisa LaMottaAbbott Nutrition has “invested considerably” in marketing to restore its reputation with consumers after its third-quarter infant formula sales were slowed by a recall in China.

Nov 6, 2024 | insights.citeline.com | Lisa LaMotta |John H Davis |Sten Stovall

Deal Watch: Auxilium Accepts Endo Buyout Rather Than Completing Purchase Of QLT Shell13 Oct 2014 • By Lisa LaMotta, John Davis, and Sten StovallActavis continues filling out its portfolio by acquiring Durata, but leaves room for other transformational deals. Impax moves strongly into generics and adds an FDA-licensed manufacturing site in buying three companies under the Tower Holdings umbrella.

Oct 18, 2024 | insights.citeline.com | Lisa LaMotta |Jessica Merrill

Deal Watch: Auxilium Joins The Tax-Inversion Wave As BIO Keeps The Deal Tide HighEndo expanded its generics business by purchasing Dava, EMD Serono partnered with Mersana on antibody-drug conjugates and Ligand in-licensed a cancer and autoimmune disease candidate from TG Therapeutics. It was all part of a hectic deal-making week coinciding with the annual BIO conference in San Diego.

Oct 15, 2024 | insights.citeline.com | Paul Bonanos |Michael Goodman |Lisa LaMotta

Deals of the Week: GSK Working On Three Deals, Agilent/Dako21 May 2012 • By Paul Bonanos, Michael Goodman, and Lisa LaMottaGlaxoSmithKline tries to turn partnerships into acquisitions with varying results, as one company accepts a buy-out while another adopts a poison-pill strategy.